Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews
Resumen
RAPID REVIEW – April 16th, 2020. (The information included in this review reflects the evidence as of the date posted in the document. Updates will be developed according to new available evidence) Disclaimer This document includes the results of a rapid systematic review of current available literature. The information included in this review reflects the evidence as of the date posted in the document. Yet, recognizing that there are numerous ongoing clinical studies, PAHO will periodically update these reviews and corresponding recommendations as new evidence becomes available... The following evidence-database was complied to orient the published studies thus far and will endeavor to add to this table list as research is released into the public space. The drugs currently under review are: meplazumab, ivermectin, siltuximab, danoprevir, tocilizumab, favipiravir, darunavir, nelfinavir, remdesivir, cloroquine/hydroxychloroquine, convalescent plasma, corticosteroids, umifenovir and lopinavir/ritonavir.